GAMMA Investing LLC Has $1.51 Million Holdings in Omnicell, Inc. (NASDAQ:OMCL)

GAMMA Investing LLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 2,892.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,211 shares of the company's stock after buying an additional 41,767 shares during the period. GAMMA Investing LLC owned about 0.09% of Omnicell worth $1,511,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of OMCL. Smartleaf Asset Management LLC raised its stake in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after buying an additional 273 shares during the period. Summit Investment Advisors Inc. increased its stake in Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock worth $213,000 after acquiring an additional 307 shares during the last quarter. Van ECK Associates Corp increased its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. increased its stake in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after acquiring an additional 355 shares during the last quarter. Finally, Redmond Asset Management LLC increased its stake in Omnicell by 0.3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after acquiring an additional 371 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on OMCL. Wells Fargo & Company reiterated an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Finally, JPMorgan Chase & Co. reduced their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Omnicell has a consensus rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Price Performance

NASDAQ:OMCL opened at $29.25 on Friday. The firm's fifty day moving average is $29.77 and its two-hundred day moving average is $37.01. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 108.34, a PEG ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. Research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.